- Home
- RAPP vs VSTM Comparison
RAPP vs VSTM Comparison
Compare RAPP & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAPP
- VSTM
- Stock Information
- Founded
- RAPP 2022
- VSTM 2010
- Country
- RAPP United States
- VSTM United States
- Employees
- RAPP N/A
- VSTM N/A
- Industry
- RAPP
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- RAPP
- VSTM Health Care
- Exchange
- RAPP Nasdaq
- VSTM Nasdaq
- Market Cap
- RAPP 439.4M
- VSTM 425.9M
- IPO Year
- RAPP 2024
- VSTM 2012
- Fundamental
- Price
- RAPP $16.05
- VSTM $6.14
- Analyst Decision
- RAPP Strong Buy
- VSTM Strong Buy
- Analyst Count
- RAPP 2
- VSTM 9
- Target Price
- RAPP $35.00
- VSTM $12.63
- AVG Volume (30 Days)
- RAPP 177.9K
- VSTM 2.5M
- Earning Date
- RAPP 08-07-2025
- VSTM 08-07-2025
- Dividend Yield
- RAPP N/A
- VSTM N/A
- EPS Growth
- RAPP N/A
- VSTM N/A
- EPS
- RAPP N/A
- VSTM N/A
- Revenue
- RAPP N/A
- VSTM $10,000,000.00
- Revenue This Year
- RAPP N/A
- VSTM $81.24
- Revenue Next Year
- RAPP N/A
- VSTM $408.06
- P/E Ratio
- RAPP N/A
- VSTM N/A
- Revenue Growth
- RAPP N/A
- VSTM N/A
- 52 Week Low
- RAPP $6.43
- VSTM $2.10
- 52 Week High
- RAPP $29.74
- VSTM $9.10
- Technical
- Relative Strength Index (RSI)
- RAPP N/A
- VSTM 66.83
- Support Level
- RAPP N/A
- VSTM $4.86
- Resistance Level
- RAPP N/A
- VSTM $5.62
- Average True Range (ATR)
- RAPP 0.00
- VSTM 0.38
- MACD
- RAPP 0.00
- VSTM 0.18
- Stochastic Oscillator
- RAPP 0.00
- VSTM 91.23
About RAPP Rapport Therapeutics Inc. Common Stock
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.